The global public relations group of inVentiv Health helps launch brands and build the reputations of companies working to improve human health. It includes four PR agencies—Allidura Consumer, Biosector 2, Chamberlain Healthcare PR, and Chandler Chicco Agency—that offer best-in-class capabilities spanning public relations, digital and social media, issues management, stakeholder engagement, and analytics and measurement. Integration with advertising and medical communications agencies at inVentiv Health drives complete communications solutions that build corporate and brand value and deliver on the bottom line.
inVentiv Health is a top-tier professional services organization that accelerates the clinical and commercial success of biopharmaceutical companies worldwide. For more information, visit inVentivHealth.com.
inVentiv Health PR Group
450 West 15th Street, Suite 700
New York, NY 10011
212-229-8400
www.inventivhealth-pr.com
LinkedIn: inVentiv Health Public Relations Group
Facebook: inVentiv Health Public Relations Group
Twitter: @inVentivPR
Leadership:
Jeanine O’Kane, Managing Director, inVentiv Health PR Group U.S.
New Business Contact:
Eleanor Petigrow, Head of Business Development
212-229-8450
eleanor.petigrow@inventivhealth.com or prgroup@inventivhealth.com
Year Founded: 1995
Parent Company: inVentiv Health
Number of Employees: 395
Areas of Expertise:
Communications for healthcare and pharma companies. Capabilities include:
- Advocacy relations
- Clinical trial recruitment
- Communications and message training
- Corporate communications & reputation
- management
- Crisis and issues management
- Data and publication support
- Digital & social media
- Disease awareness campaigns
- Employee and internal communications
- Measurement & analytics
- Media relations and publicity
- Medical meeting support
- Product approval/launch
- Stakeholder and influencer mapping
What’s New in 2016:
Whitepaper: Sharing the Mission to Conquer Rare Diseases
This report from inVentiv Health Public Relations Group—based on several months of extensive research and in-depth interviews—takes a deeper look at the dynamics currently shaping collaboration between biopharmaceutical companies and patient advocacy groups in rare disease and how future roles will be defined.
